Supporting Research for Low-Cost Solutions

Few people know that fluvoxamine plus caffeine equals headaches, jitters, and insomnia-- including doctors who prescribe it. Not many people take caffeine seriously and don't remember that it is a serious drug! This website grew out of a concern that side effects could derail the important clinical trials that were testing fluvoxamine against COVID-19. In several initial trials, fluvoxamine had kept people out of the hospital, and it was important to find out whether the anti-COVID effect held up in bigger studies. Plus, some people take Luvox for depression or OCD as well, and don't understand why they feel nauseous and jittery and can't sleep. In fact, the large national COVID-OUT study ended up testing only a half-dose of fluvoxamine -- 50 mg twice a day, instead of 100 mg twice a day -- for exactly that reason (concern about side effects). Not surprisingly, it wasn't as effective as in previous studies!​ The half-dose of fluvoxamine didn't actually come out looking that great against COVID in the big trial (actually, an old diabetes drug called metformin did), but now we know.

This site is an independent project of E. Lissner, a trustee of Parsemus Foundation, which works to create meaningful improvements in human and animal health and welfare by advancing innovative medical research, particularly low-cost approaches neglected by the pharmaceutical industry. The page was inspired by the University of Minnesota's COVID trial we were involved in, by a family history (slow metabolizers on one side of the family), and by the realization of how little-known this interaction is.